Compare Cytokinetics Inc (CYTK) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Consolidated Edison, Inc. — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Consolidated Edison, Inc. trades at $111.89 (market cap $41.26B). The key difference: Consolidated Edison, Inc. is far larger — about 3.7× Cytokinetics Inc's market cap, and Consolidated Edison, Inc. pays a 3.1% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | ED | |
|---|---|---|
Market Cap | $11.12B | $41.26B |
Sector | Technology | Utilities |
52-Week High | $87.26 | $115.46 |
52-Week Low | $33.23 | $95.37 |
Enterprise Value | $11.59B | $68.29B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Consolidated Edison (ED) trades at $111.82, up 0.63% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings but maintains stable profitability with a 12.52% net margin. Recent news highlights grid upgrades to meet rising data center demand and the launch of New York's largest electric school bus fleet, supporting long-term growth initiatives.
ED offers a defensive utility profile with a 3.3% dividend yield and 52-year dividend growth streak. However, analyst consensus is cautious with 67% hold ratings and a $103.50 price target below current levels. Key risks include capital expenditure pressures from grid modernization and interest rate sensitivity due to high debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
